Literature DB >> 31332020

XPO1 Inhibitor Approved for Multiple Myeloma.

.   

Abstract

The FDA granted accelerated approval to selinexor plus low-dose dexamethasone for triple-class refractory multiple myeloma, despite an advisory panel's concerns about the drug's toxicity and the lack of randomized clinical data. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID： 31332020     DOI： 10.1158/2159-8290.CD-NB2019-085

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  9 in total

1.  Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.

Authors:  Jithma P Abeykoon; Xiaosheng Wu; Kevin E Nowakowski; Surendra Dasari; Jonas Paludo; S John Weroha; Chunling Hu; Xiaonan Hou; Jann N Sarkaria; Ann C Mladek; Jessica L Phillips; Andrew L Feldman; Aishwarya Ravindran; Rebecca L King; Justin Boysen; Mary J Stenson; Ryan M Carr; Michelle K Manske; Julian R Molina; Prashant Kapoor; Sameer A Parikh; Shaji Kumar; Steven I Robinson; Jia Yu; Judy C Boughey; Liewei Wang; Matthew P Goetz; Fergus J Couch; Mrinal M Patnaik; Thomas E Witzig
Journal:  Blood       Date:  2021-01-28       Impact factor: 22.113

2.  Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.

Authors:  Akira Inoue; Frederick S Robinson; Rosalba Minelli; Hideo Tomihara; Bahar Salimian Rizi; Johnathon L Rose; Takahiro Kodama; Sanjana Srinivasan; Angela L Harris; Andy M Zuniga; Robert A Mullinax; Xiaoyan Ma; Sahil Seth; Joseph R Daniele; Michael D Peoples; Sara Loponte; Kadir C Akdemir; Tin Oo Khor; Ningping Feng; Jason Roszik; Mary M Sobieski; David Brunell; Clifford Stephan; Virginia Giuliani; Angela K Deem; Takashi Shingu; Yonathan Lissanu Deribe; David G Menter; Timothy P Heffernan; Andrea Viale; Christopher A Bristow; Scott Kopetz; Giulio F Draetta; Giannicola Genovese; Alessandro Carugo
Journal:  Gastroenterology       Date:  2021-03-19       Impact factor: 33.883

3.  Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.

Authors:  Rachel Sexton; Zaid Mahdi; Rahman Chaudhury; Rafic Beydoun; Amro Aboukameel; Husain Y Khan; Erkan Baloglu; William Senapedis; Yosef Landesman; Anteneh Tesfaye; Steve Kim; Philip A Philip; Asfar S Azmi
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

4.  A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma.

Authors:  Jason A Somarelli; Gabrielle Rupprecht; Erdem Altunel; Etienne M Flamant; Sneha Rao; Dharshan Sivaraj; Alexander L Lazarides; Sarah M Hoskinson; Maya U Sheth; Serene Cheng; So Young Kim; Kathryn E Ware; Anika Agarwal; Mark M Cullen; Laura E Selmic; Jeffrey I Everitt; Shannon J McCall; Cindy Eward; William C Eward; David S Hsu
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

Review 5.  Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.

Authors:  He-Ming Zhou; Ji-Gang Zhang; Xue Zhang; Qin Li
Journal:  Signal Transduct Target Ther       Date:  2021-02-15

6.  Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.

Authors:  Min Sui; Meimei Xiong; Yuling Li; Qiao Zhou; Xiaofei Shen; Da Jia; Maling Gou; Qingxiang Sun
Journal:  Int J Nanomedicine       Date:  2021-04-14

Review 7.  XPO1-dependent nuclear export as a target for cancer therapy.

Authors:  Nancy G Azizian; Yulin Li
Journal:  J Hematol Oncol       Date:  2020-06-01       Impact factor: 17.388

8.  Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.

Authors:  Husain Yar Khan; James Ge; Misako Nagasaka; Amro Aboukameel; Gabriel Mpilla; Irfana Muqbil; Mark Szlaczky; Mahmoud Chaker; Erkan Baloglu; Yosef Landesman; Ramzi M Mohammad; Asfar S Azmi; Ammar Sukari
Journal:  Int J Mol Sci       Date:  2019-12-29       Impact factor: 5.923

9.  Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis.

Authors:  Lei Zhao; Baiwei Luo; Liang Wang; Wei Chen; Manyu Jiang; Nengwei Zhang
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.